Filing Details
- Accession Number:
- 0001209191-18-009413
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-12 21:00:07
- Reporting Period:
- 2018-02-09
- Accepted Time:
- 2018-02-12 21:00:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1604464 | Atara Biotherapeutics Inc. | ATRA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1403571 | D Heather Turner | C/O Atara Biotherapeutics, Inc. 611 Gateway Boulevard, Suite 900 South San Francisco CA 94080 | Former Evp, Gc & Sec. | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-02-09 | 4,596 | $36.63 | 77,112 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-09 | 4,123 | $37.38 | 72,989 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-09 | 600 | $38.63 | 72,389 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-09 | 733 | $39.66 | 71,656 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-09 | 600 | $40.62 | 71,056 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-09 | 1,562 | $41.69 | 69,494 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Transaction pursuant to Rule 10b5-1 Plan adopted September 23, 2016.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $37.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.05 to $38.05. The reporting person will provide to theissuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $39.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $39.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $41.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.35 to $41.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Billionaire Hedge Funds
